entertainment -WSS

entertainment

author：knowledge 2025-10-01 02:27:20 - browse：55

Roche HQ — SEBASTIEN BOZON/AFP via Getty Images

The multibillion-dollar hunt for what many drugmakers hope will be the next big immunotherapy target has had no shortage of twists and tea-leaf-reading. In the wee hours of Wednesday morning, it got another.

Roche confirmed it accidentally released interim data from a closely watched clinical trial testing whether blocking that target — a protein on T cells known as TIGIT — can enable non-small lung cancer patients to live longer than standard immunotherapy alone.

The announcement release came hours after Evercore analyst Umer Raffat emailed investors that he had found a presentation on a Roche media portal, presumably uploaded by accident.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： SAMSHA loosens regulations on methadone treatment centers

entertainment

WSS

Biogen says it will cut costs by $700 million, slash 1,000 jobs

What we need to know about Arena Bioworks

Congressmen charge Covid hearing ‘could have been an email’

Quicker fix for pulse oximeters urged during FDA public meeting

The haunting brain science of long Covid

Dems pitch expanding Medicare power to negotiate drug prices

Wikipedia

entertainment

hotspot

DIEP, the 'gold standard' of breast reconstruction, is under threat

Novo Nordisk to expand supply of Wegovy for U.S. patients

Heart attack and stroke risk calculators need revising

Why patients can’t get everything they want on drug pricing

Psychedelics group wrestles with new pharma identity

New Ultima Genomics DNA sequencer can read genome for $100

Medical records are filled with copy

What we need to know about Arena Bioworks

Novavax promises a turnaround & Lilly roils the obesity market

FDA drug safety: Singulair case shows systemic surveillance flaws

hotspot

What we need to know about Arena Bioworks

UHS says company favors patients whose insurance pays more

General Catalyst, Summa Health deal will turn on physician buy

Covid misinformation case heads to Supreme Court

Woodcock on FDA’s accelerated approval and her next chapter

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

entertainment

Wikipedia

hotspot

entertainment